Overcoming problems of poor drug penetration into bacteria: challenges and strategies for medicinal chemists

References

• Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev. 2010;74:417–433.
   PubMed Web of Science ®Google Scholar
• Ebejer JP, Charlton MH, Finn PW. Are the physicochemical properties of antibacterial compounds really different from other drugs? J Cheminform. 2016;8:30.
   PubMed Web of Science ®Google Scholar
• Nikaido H. Preventing drug access to targets: cell surface permeability barriers and active efflux in bacteria. Semin Cell Dev Biol. 2001;12:215–223.
   PubMed Web of Science ®Google Scholar
• Davis TD, Gerry CJ, Tan DS. General platform for systematic quantitative evaluation of small-molecule permeability in bacteria. ACS Chem Biol. 2014;9:2535–2544.
   PubMed Web of Science ®Google Scholar
• Silhavy TJ, Kahne D, Walker S. The bacterial cell envelope. Cold Spring Harb Perspect Biol. 2010;2:a000414.
   PubMed Web of Science ®Google Scholar
• Malanovic N, Lohner K. Gram-positive bacterial cell envelopes: the impact on the activity of antimicrobial peptides. Biochim Biophys Acta. 2016;1858:936–946.
   PubMed Web of Science ®Google Scholar
• Jordan S, Hutchings MI, Mascher T. Cell envelope stress response in Gram-positive bacteria. FEMS Microbiol Rev. 2008;32:107–146.
   PubMed Web of Science ®Google Scholar
• Filgueiras MH, Op den Kamp JA. Cardiolipin, a major phospholipid of Gram-positive bacteria that is not readily extractable. Biochim Biophys Acta. 1980;620:332–337.
   PubMedGoogle Scholar
• Hayhurst EJ, Kailas L, Hobbs JK, et al. Cell wall peptidoglycan architecture in Bacillus subtilis. Proc Natl Acad Sci USA. 2008;105:14603–14608.
   PubMed Web of Science ®Google Scholar
• Vollmer W, Blanot D, de Pedro MA. Peptidoglycan structure and architecture. FEMS Microbiol Rev. 2008;32:149–167.
   PubMed Web of Science ®Google Scholar
• Neuhaus FC, Baddiley J. A continuum of anionic charge: structures and functions of d-alanyl-teichoic acids in gram-positive bacteria. Microbiol Mol Biol Rev. 2003;67:686–723.
   PubMed Web of Science ®Google Scholar
• D’Elia MA, Millar KE, Beveridge TJ, et al. Wall teichoic acid polymers are dispensable for cell viability in Bacillus subtilis. J Bacteriol. 2006;188:8313–8316.
   PubMed Web of Science ®Google Scholar
• Swoboda JG, Campbell J, Meredith TC, et al. Wall teichoic acid function, biosynthesis, and inhibition. Chembiochem. 2010;11:35–45.
   PubMed Web of Science ®Google Scholar
• Navarre WW, Schneewind O. Surface proteins of gram-positive bacteria and mechanisms of their targeting to the cell wall envelope. Microbiol Mol Biol Rev. 1999;63:174–229.
   PubMed Web of Science ®Google Scholar
• Xia G, Kohler T, Peschel A. The wall teichoic acid and lipoteichoic acid polymers of Staphylococcus aureus. Int J Med Microbiol. 2010;300:148–154.
   PubMed Web of Science ®Google Scholar
• Markham PN, Neyfakh AA. Efflux-mediated drug resistance in Gram-positive bacteria. Curr Opin Microbiol. 2001;4:509–514.
   PubMed Web of Science ®Google Scholar
• Schindler BD, Kaatz GW. Multidrug efflux pumps of Gram-positive bacteria. Drug Resist Updat. 2016;27:1–13.
   PubMed Web of Science ®Google Scholar
• Beveridge TJ. Structures of Gram-negative cell walls and their derived membrane vesicles. J Bacteriol. 1999;181:4725–4733.
   PubMed Web of Science ®Google Scholar
• Delcour AH. Outer membrane permeability and antibiotic resistance. Biochim Biophys Acta. 2009;1794:808–816.
   PubMed Web of Science ®Google Scholar
• Pages JM, James CE, Winterhalter M. The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria. Nat Rev Microbiol. 2008;6:893–903.
   PubMed Web of Science ®Google Scholar
• Narita SI, Tokuda H. Bacterial lipoproteins; biogenesis, sorting and quality control. Biochim Biophys Acta. 2017;1862:1414–1423.
   PubMed Web of Science ®Google Scholar
• Narita S, Matsuyama S, Tokuda H. Lipoprotein trafficking in Escherichia coli. Arch Microbiol. 2004;182:1–6.
   PubMed Web of Science ®Google Scholar
• Wilson MM, Bernstein HD. Surface-exposed lipoproteins: an emerging secretion phenomenon in Gram-negative bacteria. Trends Microbiol. 2016;24:198–208.
   PubMed Web of Science ®Google Scholar
• Amaral L, Martins A, Spengler G, et al. Efflux pumps of Gram-negative bacteria: what they do, how they do it, with what and how to deal with them. Front Pharmacol. 2013;4:168.
   Web of Science ®Google Scholar
• Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria: an update. Drugs. 2009;69:1555–1623.
   PubMed Web of Science ®Google Scholar
• Galdiero S, Falanga A, Cantisani M, et al. Microbe-host interactions: structure and role of Gram-negative bacterial porins. Curr Protein Pept Sci. 2012;13:843–854.
   PubMed Web of Science ®Google Scholar
• Fu LM, Fu-Liu CS. Is Mycobacterium tuberculosis a closer relative to Gram-positive or Gram-negative bacterial pathogens? Tuberculosis. 2002;82:85–90.
   PubMed Web of Science ®Google Scholar
• Jackson M. The mycobacterial cell envelope—lipids. Cold Spring Harb Perspect Med. 2014;4:a021105.
   PubMed Web of Science ®Google Scholar
• Daffe M, Draper P. The envelope layers of mycobacteria with reference to their pathogenicity. Adv Microb Physiol. 1998;39:131–203.
   PubMed Web of Science ®Google Scholar
• Jarlier V, Nikaido H. Permeability barrier to hydrophilic solutes in Mycobacterium chelonei. J Bacteriol. 1990;172:1418–1423.
   PubMed Web of Science ®Google Scholar
• Zuber B, Chami M, Houssin C, et al. Direct visualization of the outer membrane of mycobacteria and corynebacteria in their native state. J Bacteriol. 2008;190:5672–5680.
   PubMed Web of Science ®Google Scholar
• Bansal-Mutalik R, Nikaido H. Mycobacterial outer membrane is a lipid bilayer and the inner membrane is unusually rich in diacyl phosphatidylinositol dimannosides. Proc Natl Acad Sci USA. 2014;111:4958–4963.
   PubMed Web of Science ®Google Scholar
• Trias J, Jarlier V, Benz R. Porins in the cell wall of mycobacteria. Science. 1992;258:1479–1481.
   PubMed Web of Science ®Google Scholar
• Ojha A, Hatfull GF. The role of iron in Mycobacterium smegmatis biofilm formation: the exochelin siderophore is essential in limiting iron conditions for biofilm formation but not for planktonic growth. Mol Microbiol. 2007;66:468–483.
   PubMed Web of Science ®Google Scholar
• Stahl C, Kubetzko S, Kaps I, et al. MspA provides the main hydrophilic pathway through the cell wall of Mycobacterium smegmatis. Mol Microbiol. 2001;40:451–464.
   PubMed Web of Science ®Google Scholar
• Wolschendorf F, Mahfoud M, Niederweis M. Porins are required for uptake of phosphates by Mycobacterium smegmatis. J Bacteriol. 2007;189:2435–2442.
   PubMed Web of Science ®Google Scholar
• Stephan J, Bender J, Wolschendorf F, et al. The growth rate of Mycobacterium smegmatis depends on sufficient porin-mediated influx of nutrients. Mol Microbiol. 2005;58:714–730.
   PubMed Web of Science ®Google Scholar
• Chiaradia L, Lefebvre C, Parra J, et al. Dissecting the mycobacterial cell envelope and defining the composition of the native mycomembrane. Sci Rep. 2017;7:12807.
   PubMed Web of Science ®Google Scholar
• Ramon-Garcia S, Martín C, Thompson CJ, et al. Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth. Antimicrob Agents Chemother. 2009;53:3675–3682.
   PubMed Web of Science ®Google Scholar
• Viveiros M, Martins M, Rodrigues L, et al. Inhibitors of mycobacterial efflux pumps as potential boosters for anti-tubercular drugs. Expert Rev Anti-Infect Ther. 2012;10:983–998.
   PubMed Web of Science ®Google Scholar
• Liu J, Takiff HE, Nikaido H. Active efflux of fluoroquinolones in Mycobacterium smegmatis mediated by LfrA, a multidrug efflux pump. J Bacteriol. 1996;178:3791–3795.
   PubMed Web of Science ®Google Scholar
• McMurry L, Petrucci RE, Levy SB. Active efflux of tetracycline encoded by four genetically different tetracycline resistance determinants in Escherichia coli. PNAS. 1980;77:3974–3977.
   PubMed Web of Science ®Google Scholar
• Hernando-Amado S, Blanco P, Alcalde-Rico M, et al. Multidrug efflux pumps as main players in intrinsic and acquired resistance to antimicrobials. Drug Resist Updat. 2016;28:13–27.
   PubMed Web of Science ®Google Scholar
• Paulsen IT, Sliwinski MK, Saier MH Jr. Microbial genome analyses: global comparisons of transport capabilities based on phylogenies, bioenergetics and substrate specificities. J Mol Biol. 1998;277:573–592.
   PubMed Web of Science ®Google Scholar
• Kumar A, Schweizer HP. Bacterial resistance to antibiotics: active efflux and reduced uptake. Adv Drug Deliv Rev. 2005;57:1486–1513.
   PubMed Web of Science ®Google Scholar
• Sun J, Deng Z, Yan A. Bacterial multidrug efflux pumps: mechanisms, physiology and pharmacological exploitations. Biochem Biophys Res Commun. 2014;453:254–267.
   PubMed Web of Science ®Google Scholar
• Marquez B. Bacterial efflux systems and efflux pumps inhibitors. Biochimie. 2005;87:1137–1147.
   PubMed Web of Science ®Google Scholar
• Moreira MAS, de Souza EC, de Moraes CA. Multidrug efflux systems in Gram-negative bacteria. Braz J Microbiol. 2004;35:19–28.
   Web of Science ®Google Scholar
• Blanco P, Hernando-Amado S, Reales-Calderon JA, et al. Bacterial multidrug efflux pumps: much more than antibiotic resistance determinants. Microorg. 2016;4:1–19.
   Google Scholar
• Krishnamoorthy G, Leus IV, Weeks JW, et al. Synergy between active efflux and outer membrane diffusion defines rules of antibiotic permeation into Gram-negative bacteria. Mbio. 2017;8:1–16.
   Web of Science ®Google Scholar
• Fralick JA. Evidence that TolC is required for functioning of the Mar/AcrAB efflux pump of Escherichia coli. J Bacteriol. 1996;178:5803–5805.
   PubMed Web of Science ®Google Scholar
• Piddock LJ. Multidrug-resistance efflux pumps - not just for resistance. Nat Rev Microbiol. 2006;4:629–636.
   PubMed Web of Science ®Google Scholar
• Du D, Wang Z, James NR, et al. Structure of the AcrAB-TolC multidrug efflux pump. Nature. 2014;509:512–515.
   PubMed Web of Science ®Google Scholar
• Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev. 2011;24:71–109.
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 1997;23:3–25.
   Web of Science ®Google Scholar
• O’Shea R, Moser HE. Physicochemical properties of antibacterial compounds: implications for drug discovery. J Med Chem. 2008;51:2871–2878.
   PubMed Web of Science ®Google Scholar
• Leeson PD, Davis AM. Time-related differences in the physical property profiles of oral drugs. J Med Chem. 2004;47:6338–6348.
   PubMed Web of Science ®Google Scholar
• Silver LL. A gestalt approach to Gram-negative entry. Bioorg Med Chem. 2016;24:6379–6389.
   PubMed Web of Science ®Google Scholar
• Vaara M. Agents that increase the permeability of the outer membrane. Microbiol Rev. 1992;56:395–411.
   PubMedGoogle Scholar
• Van Bambeke F, Pages JM, Lee VJ. Inhibitors of bacterial efflux pumps as adjuvants in antibiotic treatments and diagnostic tools for detection of resistance by efflux. Recent Pat Antiinfect Drug Discov. 2006;1:157–175.
   PubMedGoogle Scholar
• Lamers RP, Cavallari JF, Burrows LL. The efflux inhibitor phenylalanine-arginine beta-naphthylamide (PAβN) permeabilizes the outer membrane of Gram-negative bacteria. PLoS One. 2013;8:e60666.
   Web of Science ®Google Scholar
• Okandeji BO, Greenwald DM, Wroten J, et al. Synthesis and evaluation of inhibitors of bacterial drug efflux pumps of the major facilitator superfamily. Bioorg Med Chem. 2011;19:7679–7689.
   PubMedGoogle Scholar
• Lomovskaya O, Warren MS, Lee A, et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Ch. 2001;45:105–116.
   PubMed Web of Science ®Google Scholar
• Renau TE, Leger R, Flamme EM, et al. Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin. J Med Chem. 1999;42:4928–4931.
   PubMed Web of Science ®Google Scholar
• Lambert PA. Cellular impermeability and uptake of biocides and antibiotics in Gram-positive bacteria and mycobacteria. J Appl Microbiol. 2002;92:46–54.
   PubMed Web of Science ®Google Scholar
• Manchester JI, Buurman ET, Bisacchi GS, et al. Molecular determinants of AcrB-mediated bacterial efflux implications for drug discovery. J Med Chem. 2012;55:2532–2537.
   PubMed Web of Science ®Google Scholar
• Bisacchi GS, Manchester JI. A new-class antibacterial-almost. Lessons in drug discovery and development: a critical analysis of more than 50 years of effort toward ATPase inhibitors of DNA gyrase and topoisomerase IV. ACS Infect Dis. 2015;1:4–41.
   PubMed Web of Science ®Google Scholar
• Manchester JI, Dussault DD, Rose JA, et al. Discovery of a novel azaindole class of antibacterial agents targeting the ATPase domains of DNA gyrase and topoisomerase IV. Bioorg Med Chem Lett. 2012;22:5150–5156.
   PubMed Web of Science ®Google Scholar
• Richter MF, Drown BS, Riley AP, et al. Predictive compound accumulation rules yield a broad-spectrum antibiotic. Nature. 2017;545:299–304.
   PubMed Web of Science ®Google Scholar
• Kuenemann MA, Bourbon LM, Labbe CM, et al. Which three-dimensional characteristics make efficient inhibitors of protein-protein interactions? J Chem Inf Model. 2014;54:3067–3079.
   PubMed Web of Science ®Google Scholar
• Delcour AH. Outer membrane permeability and antibiotic resistance. Biochim Biophys Acta-Proteins Proteomics. 2009;1794:808–816.
   PubMed Web of Science ®Google Scholar
• Hancock RE. Alterations in outer membrane permeability. Annu Rev Microbiol. 1984;38:237–264.
   PubMed Web of Science ®Google Scholar
• Daugelavičius R, Bakienė E, Bamford DH. Stages of polymyxin B interaction with the Escherichia coli cell envelope. Antimicrob Agents Chemother. 2000;44:2969–2978.
   PubMed Web of Science ®Google Scholar
• Nikaido H, Thanassi DG. Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples. Antimicrob Agents Chemother. 1993;37:1393–1399.
   PubMed Web of Science ®Google Scholar
• Nikaido H, Vaara M. Molecular basis of bacterial outer membrane permeability. Microbiol Rev. 1985;49:1–32.
   PubMedGoogle Scholar
• Leive L, Telesetsky S, Coleman WG, et al. Tetracyclines of various hydrophobicities as a probe for permeability of Escherichia coli outer membranes. Antimicrob Agents Chemother. 1984;25:539–544.
   PubMed Web of Science ®Google Scholar
• Denis O, Rodriguez-Villalobos H, Struelens MJ. Chapter 3 - the problem of resistance A2. In: Finch RG, Greenwood D, Norrby SR, et al., editors. Antibiotic and chemotherapy. 9th ed. London: Elsevier Saunders; 2010.:24–48.
   Google Scholar
• Kaufman MB. Pharmaceutical Approval Update. P T. 2017;42:673–683.
   PubMedGoogle Scholar
• Markham A. Delafloxacin: first global approval. Drugs. 2017;77:1481–1486.
   PubMed Web of Science ®Google Scholar
• Candel FJ, Penuelas M. Delafloxacin: design, development and potential place in therapy. Drug Des Devel Ther. 2017;11:881–891.
   PubMed Web of Science ®Google Scholar
• Zgurskaya HI, Löpez CA, Gnanakaran S. Permeability barrier of Gram-negative cell envelopes and approaches to bypass it. ACS Infect Dis. 2015;1:512–522.
   PubMed Web of Science ®Google Scholar
• Chu BC, Garcia-Herrero A, Johanson TH, et al. Siderophore uptake in bacteria and the battle for iron with the host; a bird’s eye view. Biometals. 2010;23:601–611.
   PubMed Web of Science ®Google Scholar
• Page MGP. Siderophore conjugates. Annals NY Acad Sci. 2013;1277:115–126.
   PubMed Web of Science ®Google Scholar
• Saha R, Saha N, Donofrio RS, et al. Microbial siderophores: a mini review. J Basic Microbiol. 2013;53:303–317.
   PubMed Web of Science ®Google Scholar
• Ferreira D, Seca AM, Gad C, et al. Targeting human pathogenic bacteria by siderophores: a proteomics review. J Proteomics. 2016;145:153–166.
   PubMed Web of Science ®Google Scholar
• De Carvalho CCCR, Fernandes P. Siderophores as “Trojan Horses”: tackling multidrug resistance? Front Microbiol. 2014;5:290.
   PubMed Web of Science ®Google Scholar
• Ghosh M, Miller MJ. Design, synthesis, and biological evaluation of isocyanurate-based antifungal and macrolide antibiotic conjugates: iron transport-mediated drug delivery. Bioorg Med Chem. 1995;3:1519–1525.
   PubMed Web of Science ®Google Scholar
• Md-Saleh SR, Chilvers EC, Kerr KG, et al. Synthesis of citrate-ciprofloxacin conjugates. Bioorg Med Chem Lett. 2009;19:1496–1498.
   PubMed Web of Science ®Google Scholar
• Ji C, Miller MJ. Chemical syntheses and in vitro antibacterial activity of two desferrioxamine B-ciprofloxacin conjugates with potential esterase and phosphatase triggered drug release linkers. Bioorg Med Chem. 2012;20:3828–3836.
   PubMed Web of Science ®Google Scholar
• Page MGP, Dantier C, Desarbre E. In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant Gram-negative bacilli. Antimicrob Agents Chemother. 2010;54:2291–2302.
   PubMed Web of Science ®Google Scholar
• Monogue ML, Tsuji M, Yamano Y, et al. Efficacy of humanized exposures of cefiderocol (S-649266) against a diverse population of Gram-negative bacteria in a murine thigh infection model. Antimicrob Agents Chemother. 2017;61:1–10.
   Web of Science ®Google Scholar
• Pages JM, Masi M, Barbe J. Inhibitors of efflux pumps in Gram-negative bacteria. Trends Mol Med. 2005;11:382–389.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Liu Z-Q, Zheng P-Y, et al. Influence of efflux pump inhibitors on the multidrug resistance of Helicobacter pylori. World J Gastroenterol. 2010;16:1279–1284.
   PubMed Web of Science ®Google Scholar
• Olivares J, Bernardini A, Garcia-Leon G, et al. The intrinsic resistome of bacterial pathogens. Front Microbiol. 2013;4:103.
   PubMed Web of Science ®Google Scholar
• Masi M, Refregiers M, Pos KM, et al. Mechanisms of envelope permeability and antibiotic influx and efflux in Gram-negative bacteria. Nat Microbiol. 2017;2:17001.
   PubMed Web of Science ®Google Scholar
• Lomovskaya O, Warren MS, Lee A, et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother. 2001;45:105–116.
   PubMed Web of Science ®Google Scholar
• Sanchez P, Le U, Martinez JL. The efflux pump inhibitor Phe-Arg-beta-naphthylamide does not abolish the activity of the Stenotrophomonas maltophilia SmeDEF multidrug efflux pump. J Antimicrob Chemother. 2003;51:1042–1045.
   PubMed Web of Science ®Google Scholar
• Lomovskaya O, Bostian KA. Practical applications and feasibility of efflux pump inhibitors in the clinic–a vision for applied use. Biochem Pharmacol. 2006;71:910–918.
   PubMed Web of Science ®Google Scholar
• Nakayama K, Ishida Y, Ohtsuka M, et al. MexAB-OprM-specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 1: discovery and early strategies for lead optimization. Bioorg Med Chem Lett. 2003;13:4201–4204.
   PubMed Web of Science ®Google Scholar
• Yoshida K, Nakayama K, Ohtsuka M, et al. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate. Bioorg Med Chem. 2007;15:7087–7097.
   PubMed Web of Science ®Google Scholar
• Bohnert JA, Kern WV. Selected arylpiperazines are capable of reversing multidrug resistance in Escherichia coli overexpressing RND efflux pumps. Antimicrob Agents Chemother. 2005;49:849–852.
   PubMed Web of Science ®Google Scholar
• Sabatini S, Gosetto F, Manfroni G, et al. Evolution from a natural flavones nucleus to obtain 2-(4-propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump. J Med Chem. 2011;54:5722–5736.
   PubMed Web of Science ®Google Scholar
• Poisson J, Le Hir A, Goutarel R, et al. Isolation of reserpine from roots of Rauwolfia vomitoria Afz. C R Hebd Seances Acad Sci. 1954;238:1607–1609.
   PubMedGoogle Scholar
• Neyfakh AA, Bidnenko VE, Chen LB. Efflux-mediated multidrug resistance in Bacillus subtilis: similarities and dissimilarities with the mammalian system. PNAS. 1991;88:4781–4785.
   PubMed Web of Science ®Google Scholar
• Kumar S, Mukherjee MM, Varela MF. Modulation of bacterial multidrug resistance efflux pumps of the major facilitator superfamily. Int J Bacteriol. 2013;pii:2041412013.
   Google Scholar
• Mullin S, Mani N, Grossman TH. Inhibition of antibiotic efflux in bacteria by the novel multidrug resistance inhibitors biricodar (VX-710) and timcodar (VX-853). Antimicrob Agents Chemother. 2004;48:4171–4176.
   PubMed Web of Science ®Google Scholar
• Handzlik J, Matys A, Kieć-Kononowicz K. Recent advances in multi-drug resistance (MDR) efflux pump inhibitors of Gram-positive bacteria S. aureus. Antibiotics. 2013;2:28–45.
   Google Scholar
• Pinto-Alphandary H, Andremont A, Couvreur P. Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications. Int J Antimicrob Agents. 2000;13:155–168.
   PubMed Web of Science ®Google Scholar
• Abed N, Couvreur P. Nanocarriers for antibiotics: a promising solution to treat intracellular bacterial infections. Int J Antimicrob Agents. 2014;43:485–496.
   PubMed Web of Science ®Google Scholar
• Drulis-Kawa Z, Dorotkiewicz-Jach A. Liposomes as delivery systems for antibiotics. Int J Pharm. 2010;387:187–198.
   PubMed Web of Science ®Google Scholar
• Nicolosi D, Cupri S, Genovese C, et al. Nanotechnology approaches for antibacterial drug delivery: preparation and microbiological evaluation of fusogenic liposomes carrying fusidic acid. Int J Antimicrob Agents. 2015;45:622–626.
   PubMed Web of Science ®Google Scholar
• Elhissi A. Liposomes for pulmonary drug delivery: the role of formulation and inhalation device design. Curr Pharm Des. 2017;23:362–372.
   PubMed Web of Science ®Google Scholar
• Sharma A, Sharma US. Liposomes in drug delivery: progress and limitations. Int J Pharm. 1997;154:123–140.
   Web of Science ®Google Scholar
• Parkin J, Chavent M, Khalid S. Molecular simulations of Gram-negative bacterial membranes: a vignette of some recent successes. Biophys J. 2015;109:461–468.
   PubMed Web of Science ®Google Scholar
• Iyer R, Sylvester MA, Velez-Vega C, et al. Whole-cell-based assay to evaluate structure permeation relationships for carbapenem passage through the Pseudomonas aeruginosa Porin OprD. ACS Infect Dis. 2017;3:310–319.
   PubMed Web of Science ®Google Scholar
• Stokes JM, MacNair CR, Ilyas B, et al. Pentamidine sensitizes Gram-negative pathogens to antibiotics and overcomes acquired colistin resistance. Nature Microbiol. 2017;2:1–21.
   Web of Science ®Google Scholar